©2024 Stanford Medicine
Pharmacology of Aminophylline for Acute Kidney Injury in Neonates
Not Recruiting
Trial ID: NCT02276170
Purpose
Acute kidney injury (AKI) in critically ill neonates is common and associated with
significant morbidity and mortality. No targeted therapeutic treatment strategies have been
established for AKI in neonates. Within a clinical pharmacokinetic and pharmacodynamic
conceptual framework, this project will examine the medication aminophylline as a potential
treatment approach for AKI.
Eligibility
Inclusion Criteria:
- Neonate < 3 months post natal age
- Diagnosed with acute kidney injury (AKI)
- Receiving aminophylline for AKI treatment as per local standard of care.
Exclusion Criteria:
- Presence of anatomical renal anomaly based on postnatal evaluation of the patient
(hydronephrosis, multicystic kidney, renal agenesis, renal dysplasia, polycystic
kidney, or obstructive uropathy)
- Patient on renal replacement therapy
- Major genetic abnormalities (trisomy 13, 18 or 21).
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305